{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:10:06Z","timestamp":1756372206912,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,11,30]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Vasculitis and other autoimmune conditions are known complications of tumour necrosis factor alpha (TNF-\u03b1) inhibitor use. By definition, TNF-\u03b1 inhibitor induced vasculitis is a secondary systemic vasculitis. However, its phenotype is varied and can present as an isolated vasculitic neuropathy. This presents a diagnostic challenge as the gold standard for diagnosis of a vasculitic neuropathy is a peripheral nerve biopsy that meets predefined histopathological criteria. Given the poor sensitivity of the peripheral nerve biopsy, it is important that clinicians take a good history and maintain a high index of suspicion, as this is a treatable iatrogenic condition. Here we present a case of adalimumab-induced sensory vasculitic neuropathy, treated according to the Peripheral Nerve Society guideline for non-systemic vasculitic neuropathy, given her disease phenotype.<\/jats:p>","DOI":"10.1136\/bcr-2021-246401","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T10:48:12Z","timestamp":1642416492000},"page":"e246401","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Adalimumab-induced sensory vasculitic neuropathy"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3933-0467","authenticated-orcid":false,"given":"Nicholas Keyi","family":"Sim","sequence":"first","affiliation":[{"name":"Department of Neurology, Calderdale and Huddersfield NHS Foundation Trust, Halifax, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azzam","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taimour","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya Devi","family":"Shanmugarajah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"2025082801312215000_15.1.e246401.1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181441a68"},{"key":"2025082801312215000_15.1.e246401.2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20924"},{"key":"2025082801312215000_15.1.e246401.3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jns.12147","article-title":"Anti-TNF alpha medications and neuropathy","volume":"20","author":"Tsouni","year":"2015","journal-title":"J Peripher Nerv Syst"},{"key":"2025082801312215000_15.1.e246401.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.04.011"},{"key":"2025082801312215000_15.1.e246401.5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrneurol.2017.42","article-title":"The nonsystemic vasculitic neuropathies","volume":"13","author":"Collins","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2025082801312215000_15.1.e246401.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00281.x"},{"key":"2025082801312215000_15.1.e246401.7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.vaccine.2015.11.047","article-title":"Vasculitic peripheral neuropathy: case definition and guidelines for collection, analysis, and presentation of immunisation safety data","volume":"35","author":"Hadden","year":"2017","journal-title":"Vaccine"},{"key":"2025082801312215000_15.1.e246401.8","first-page":"12","article-title":"Drug-induced vasculitis: a clinical and pathological review","volume":"70","author":"Radi\u0107","year":"2012","journal-title":"Neth J Med"},{"key":"2025082801312215000_15.1.e246401.9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/WCO.0000000000000727","article-title":"Update on classification, epidemiology, clinical phenotype and imaging of the Nonsystemic vasculitic neuropathies","volume":"32","author":"Collins","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"2025082801312215000_15.1.e246401.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2628"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-246401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:31:30Z","timestamp":1756369890000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-246401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,17]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/bcr-2021-246401"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-246401","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}